Genetic Cancer Screening

Personalized Genetic Testing provides an invaluable service to physicians and patients throughout the U.S. with our genetic cancer screening tests. 

Thousands of Tests Performed

Providing doctors with the information needed to determine the best medicines and treatments for each of their patients.

20+ Years Experience

Experience in biotechnology, pharmaceutical, hematology, flow cytometry, clinical molecular biology, immunology, and chemistry industries.

Fast 5-Day Turnaround

Using the latest technologies from the leaders in the industry, our process is 3 times faster than competitor’s analysis methods.

Accurate Reporting

Through Coriell Institute, backed by over 60 years of research experience providing the quality control required for validation in pharmacogenetics testing.

The PGT Somatic Mutations Panel offers detection of somatic mutations in solid tumors by Cast PCR Technology.

PGT Somatic Mutations for Solid Tumors Panel provides genetic results for:
BRAF Somatic mutations in the BRAF gene are common in several types of cancer. The V600E mutation is the most common BRAF gene mutation found in human cancers. This mutation has frequently been found in an aggressive form of skin cancer called melanoma as well as in cancers of the colon and rectum, ovary, and thyroid gland.
TP53 Breast cancer, soft tissue sarcoma, osteosarcoma (bone cancer), leukemia, brain tumors, adrenocortical carcinoma (cancer of the adrenal glands)
PTEN Breast, thyroid, endometrial (uterine lining).
APC Colorectal cancer, multiple non-malignant colon polyps, and both non-cancerous (benign) and cancerous tumors in the small intestine
MEN1 Pancreatic endocrine tumors and (usually benign) parathyroid and pituitary gland tumors
RET Medullary thyroid cancer and pheochromocytoma (benign adrenal gland tumor)
RB1 Eye cancer (cancer of the retina), pinealoma (cancer of the pineal gland), osteosarcoma, melanoma, and soft tissue sarcoma
VHL Kidney cancer and multiple noncancerous tumors
EGFR At least eight mutations in the EGFR gene have been associated with lung cancer, a disease in which certain cells in the lung become abnormal and multiply uncontrollably to form a tumor.
AKT1 The Glu17Lys mutation in the AKT1 gene has also been found in a small percentage of breast, ovarian, and colorectal cancers. The mutation abnormally activates AKT1 kinase, allowing cells to grow and divide without control or order. This disordered cell proliferation leads to the development of cancerous tumors. Although the Glu17Lys mutation has been reported in only a few types of cancer, increased activity (expression) of the AKT1 gene is found in many types of cancer.
CTNNB1 Mutations in the CTNNB1 gene can cause a type of aggressive but noncancerous (benign) growth called a desmoid tumor. Somatic mutations in the CTNNB1 gene are found in almost all pilomatricomas, a type of benign skin tumor associated with hair follicles.